New COG Series Advisory Board Announced
PBC Group, the organisers behind the renowned COG Series of meetings, is thrilled to introduce their newly formed Advisory Board. This diverse group of industry leaders will play a crucial role in shaping the future of the COG Series, ensuring that these events continue to deliver unparalleled value to the clinical research community.
The Advisory Board brings together a wealth of experience and expertise from across the clinical research landscape. Each member has been carefully selected for their unique insights and their ability to drive meaningful change within the industry.
The members of the PBC Group Advisory Board include:
Helen Blanco, Chief Operating Officer at Node Pharma
Lisa Chamberlain James, Owner & Senior Partner at Trilogy Writing & Consulting, An Indegene Company and TriloDocs
Andy Thurstan, Senior Director of Patient Services at Wave Life Sciences
Bornadata (Bonnie) Bain, Ph.D., President & CEO of Global Healthcare at Ipsos
Joan Chambers, Senior Consultant at Tufts Center for the Study of Drug Development
Dana Niedzielska, Senior Vice President of Global Clinical Operations at Everest Clinical Research
Phill Gallacher, Senior Vice President, Head of Clinical Operations & Program Management at Cullinan Therapeutics
Meet the board here: https://www.thepbcgroup.com/advisory-board
With the guidance and support of this exceptional group, PBC Group is poised to take the COG Series to new heights. The Advisory Board will work closely with the PBC Group team to craft compelling agendas, identify emerging trends, and ensure that each event delivers on its promise to provide an unmatched experience for attendees.
As the clinical research industry continues to evolve at a rapid pace, the insights and expertise of the Advisory Board will be invaluable in navigating the challenges and opportunities that lie ahead. PBC Group is confident that, together with their new Advisory Board, they will continue to set the standard for clinical trial industry events worldwide.
留言